Oncology Topic Homepage

CLL Knowledge Centre

,CLL KC

Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the Western world.1,2 In the UK, CLL accounts for 1% of all new cancer cases and 38% of all leukaemias.3

The new CLL Knowledge Centre provides healthcare professionals with important information to aid the treatment and management of patients with the disease. Content is arranged within three main areas: ‘Disease awareness’, ‘Events’ and ‘Resources’.

Healthcare professionals will find sections on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment, management, an upcoming events calendar and useful external links.

We are conducting a short survey regarding educational needs of healthcare professionals in relation to chronic lymphocytic leukaemia (CLL) and other haematological malignancies.
The questions will take approximately 5-10 minutes of your time to complete and your input will be much appreciated.

  1. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013 Nov 28;122(23):3723-34.
  2. Gibson J, Iland HJ, Larsen SR, Brown CM, Joshua DE. Leukaemias into the 21st century. Part 2: the chronic leukaemias. Intern Med J. 2013 May;43(5):484-94.
  3. CRUK (Cancer Research UK) 2014: Chronic lymphocytic leukaemia (CLL) incidence statistics. Updated June 2014. Accessed 25.03.15. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll/incidence

Prostate Cancer Learning Hub

,Prostate Cancer Learning Hub

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.

The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
  2. Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.

     

Soft Tissue Sarcoma

Soft Tissue Sarcoma

Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.

Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1

For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.

Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.


References

  1. . Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.

Anti-Infectives Knowledge Network CDI

,AIKN CDI

The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the area of anti-infectives.

Recent content updates include:

Please remember to return often to read updated news, clinical insights, and essential information from the latest congresses.

Anti-Infectives Knowledge Network IFI

,AIKN IFI

This educational resource is sponsored by Astellas Pharma EMEA and assembles the expertise of key thinkers in the area of anti-infectives with a focus on invasive fungal infections.

Ensure you return often to make the most of regular updates to this resource including congress highlights, industry reports, policy changes, clinical guidelines and downloadable materials (e.g. presentation slides) from major medical events.

Latest update:

The congresses section has been updated with a report from the ‘Integrating Critical Care and Haemato-oncology’ meeting held in Berlin, November 2014. Experts gathered to share opinion and debate on the changing nature of care for haemato-oncology patients requiring critical care. View this report for free here.

August 2015 MYC/15/0023/EUa

Clinical Case Studies

Non-Small Cell Lung Cancer (NSCLC)

Respiratory Medicine & Allergy: Lung Cancer

Suma Kumar, Guy's and St Thomas' NHS Foundation Trust, London, UK
Richard Leach, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 68-year-old man presented with a four-week history of left-sided, dull, aching chest pain. He had known ischaemic heart disease, previous coronary artery bypass grafting, chronic obstructive pulmonary disease and treated duodenal ulceration.

Amiodarone Pulmonary Toxicity

Respiratory Medicine & Allergy: Non granuloma interstitial lung disease

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Boris Lams, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Christopher Kosky, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London , UK

Case History
A 72-year-old woman presented to hospital with shortness of breath. Two years prior to presentation she had been commenced on amiodarone 200 mg a day for non-sustained ventricular tachycardia.

Latest News

Medical Videos

Eribulin Trial Success
Eribulin Trial Success
An Overview of Pancreatic NET and the Available Treatments
An Overview of Pancreatic NET and the Available Treatments
New Developments in the Treatment of Breast Cancer
New Developments in the Treatment of Breast Cancer
Surviving Advanced Breast Cancer
Surviving Advanced Breast Cancer
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
An Animation Explaining the Development of Lymphoma
An Animation Explaining the Development of Lymphoma
HPV Vaccine
HPV Vaccine
Cancer Vaccines- Dr. Kelvin Lee
Cancer Vaccines- Dr. Kelvin Lee

Recent Drug Updates

Medical Journal Abstracts on Oncology

A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.

3 days ago -  A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.

Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM). Despite that high TMZ potential, progression of disease and recurrence ...

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

9 days ago -  Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Background: Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed ...

Medical Images

Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
Bronchogenic cyst
Bronchogenic cyst
Sarcoidosis - chest radiograph
Sarcoidosis - chest radiograph
Amiodarone Pulmonary Toxicity
Amiodarone Pulmonary Toxicity
Pulmonary nodule
Pulmonary nodule
Sarcoidosis - radiograph showing interstitial shadowing
Sarcoidosis - radiograph showing interstitial shadowing
Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Hematoxylin and eosin stain
Hematoxylin and eosin stain
Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC)

Clinical Guidelines

Prostate Cancer: ESMO Clinical Practice Guidelines

Jul 2015

Prostate cancer is reported as the second most common cancer in men. An update of the ESMO Clinical..

... Practice Guideline provides information on the current management of prostate cancer including recommendations for screening and diagnosis, along with stage-matched therapeutic strategies.

Suspected cancer: recognition and referral

Jun 2015

This guideline updates and replaces NICE clinical guideline CG27 (published June 2005). It offers..

... evidence-based advice on the recognition of and referral for suspected cancer in children, young people and adults.

This guideline covers the recognition and selection for referral or investigation in primary care of people of all ages, including children and young people, who may have cancer. Although we have used the terms 'men' and 'women' for recommendations on gender-related cancers, these recommendations also extend to people who have changed or are in the process of changing gender, and who retain the relevant organs.

The guideline aims to help people understand what to expect if they have symptoms that may suggest cancer. It should also help those in secondary care to understand which services should be provided for people with suspected cancer. Finally, these recommendations are recommendations, not requirements, and they are not intended to override clinical judgement.

The recommendations in this guideline have been organised into 3 separate sections to help clinicians find the relevant information easily. In the first, the recommendations are organised by cancer site. There is a section covering patient support, safety netting and the diagnostic process. Then, for those wanting to find recommendations on specific symptoms and primary care investigations, the recommendations are in a section organised by symptoms and investigation findings.

Online CME

Truth and Consequences: Treating Bone Metastases in Castration-Resistant Prostate Cancer

This activity is intended for oncologists, urologists, and other clinicians who treat men with metastatic castration-resistant prostate cancer (mCRPC). The goal of this activity is to improve the knowledge and...

The Prostate: Clinical Examination

Learning outcomes - After completing this module, you should know: The indications for digital rectal examination, How to talk to patients about the examination, How to carry out the examination,...

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice

This activity is intended for oncologists, urologists, and other clinicians who treat men with castration-resistant prostate cancer (CRPC). The goal of this activity is to improve the knowledge on the...

Clinical Trials

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Sat 01 Aug 2015

The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs ...

A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer (pyruvate)

Sat 01 Aug 2015

This is a pilot study evaluating pre-surgical patients with histologically confirmed localized prostate cancer who receive infusion with hyperpolarized pyruvate (13C) injection and undergo ...

Back to top